Aperiomics has chosen Loudoun County to house its corporate HQ
Wednesday, June 5, 2019
Aperiomics Inc., a Northern Virginia biotech with a test to diagnose mysterious chronic infections, is relocating its corporate headquarters within Loudoun County.
The local startup will move from 45085 University Drive in Ashburn to a 4,700-square-foot space at 45925 Horseshoe Drive in Sterling, about 10 minutes down the road. Lease terms are still being finalized, CEO Crystal Icenhour said, and the company is planning to move in June.
The building, owned by Franklin Street Properties Corp., is within one of the county’s two opportunity zones. Opportunity zones are census tracts identified in the 2017 tax reform law that offer incentives for investment of capital gains.
“I think the benefit of being there is the incentives to have other groups come in after us and continue to develop and put companies in,” Icenhour said.
The location was attractive, she said, because of proximity to surrounding health care leaders, the area’s growing reputation as a tech hub and access to nearby data centers, a benefit for the company’s genomic research.
“The IT infrastructure and talent in Loudoun County is unparalleled in the world, so that had a huge bearing on why we chose to stay in the area,” said Icenhour, who has worked with the county and state of Virginia to help diversify its economy by incentivizing biotech companies to locate there.
The Loudoun County Board of Supervisors will consider a $75,000 commercial business incentive fund grant that would support the development of an in-house lab for Aperiomics, to be constructed in this building, according to the company. Loudoun County Economic Development worked with the company’s leadership team in its search for a long-term base.
“It is vital to us to support cutting edge companies like Aperiomics as the County diversifies its economy and grows the ecosystem for biotech companies,” said Buddy Rizer, Loudoun County Economic Development’s executive director, in a statement.
“Loudoun is well-positioned at the nexus of health and data and Aperiomics is leading this charge.”
The move comes as Aperiomics continues building up its team, expecting to have 12 employees — double its count just a couple of months ago — by July.
The company is nearing the close of its $2 million Series A round, now 85% committed, Icenhour said. South Carolina angel group VentureSouth is leading the raise. To date, the startup has raised about $1.8 million in government grant funding and $512,000 in seed funding, which closed in September 2017.
Aperiomics’ test is designed to identify every known pathogen to reveal causes of unsuccessfully diagnosed illnesses. It’s been used to help physicians treat patients with intestinal parasites unidentified for years, a chronic bladder condition called interstitial cystitis and other infections. The company was featured on NBC’s “Today Show” last month.